Genscript Biotech (G51) AI Stock Analysis

0 Followers

Genscript Biotech

(Frankfurt:G51)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong growth and marginsThe core Life Science Services segment combines substantial expected growth with strong profitability targets. This indicates that demand expansion is not being purchased through weak economics, supporting reinvestment, operating leverage, and durable earnings quality over the next several quarters.

Negative Factors

Highly volatile bottom-line profitabilityAlthough operating margins improved, the sharp swing from exceptional profit to a substantial net loss shows that reported earnings are not yet stable. This volatility can weaken confidence in recurring profitability and make internal funding and performance assessment less predictable.

Genscript Biotech (G51) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.63B
Dividend Yield: ―
Average Volume (3M): 400
Price to Earnings (P/E): -14.1
Beta (1Y): 0.92
Revenue Growth: 43.29%
EPS Growth: -118.54%
Country: Germany
Employees: 6,135
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Genscript Biotech Business Overview & Revenue Model

Company Description

Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing b...

Genscript Biotech Earnings Call Summary

Earnings Call Date:Aug 17, 2026(Q2-2026)|% Change Since:40.30%|Next Earnings Date:May 08, 2023

Earnings Call SentimentPositive

Overall the call was strongly positive: the company reported robust top-line growth (USD 404.2M, +27.3%), record adjusted net profit (+203.3% to USD 62.5M), significant margin expansion and raised guidance, while highlighting clear strategic advantages in AI-enabled validation and a strong balance sheet. The main negatives are a still-unprofitable ProBio (though materially improved), Bestzyme's modest growth and widened operating loss, and execution/demand risks tied to the pace of AIDD adoption and scaling protein-side automation. On balance, highlights substantially outweigh lowlights.

Positive Updates

Strong Group Revenue Growth

Total revenue reached USD 404.2 million, up 27.3% year-over-year, driven by broad-based demand across segments.

Negative Updates

Bestzyme Slow Growth and Increased Operating Loss

Bestzyme revenue growth was modest at +7.4% YoY and adjusted operating loss widened to USD 1.3 million (from a USD 0.6 million loss in H1 2025), reflecting deliberate investment but near-term profitability pressures.

Company Guidance

Management raised full‑year guidance: Life Science Services revenue growth 25–30% with adjusted gross margin >55% and adjusted operating margin >25%; ProBio revenue growth 25–30% with positive EBITDA expected in 2027; and Bestzyme revenue growth 8–10% with adjusted gross margin >43%. This follows a strong H1 baseline (group revenue US$404.2M, +27.3% YoY; adjusted net profit US$62.5M, +203.3%; group gross profit US$206.7M, +48%); LSG delivered US$319M revenue (+28.8%), adjusted gross profit US$185M (+46.1%) and adjusted operating profit US$94M (+102.8%) with adjusted gross margin 57.8% (55.4% ex U.S. tariff refunds) and operating margin 29.5% (27.1% same basis); ProBio H1 revenue US$61.1M (+34.2%), adjusted gross profit US$8.3M and adjusted EBITDA loss narrowed to US$6.5M (vs. -US$16.8M); Bestzyme H1 revenue US$30.4M (+7.4%) and adjusted gross profit US$13M (+14%). Management also disclosed H1 CapEx US$48.4M and full‑year CapEx ~US$130M, cash ≈US$830M, a 1.5x YoY surge in gene‑to‑protein ROI, and expects AIDD orders to double in H2 as a driver of continued upside.

Genscript Biotech Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:G51 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2269	79Outperform	HKD 204.30B	34.83	10.51%	―	21.93%	21.94%
HK:1521	66Neutral	HKD 4.33B	51.11	3.02%	―	10.32%	178.23%
HK:6821	55Neutral	HKD 61.98B	46.15	6.66%	1.21%	23.95%	18.73%
HK:1873	52Neutral	HKD 2.76B	13.52	4.45%	―	7.38%	7.90%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:3759	46Neutral	HKD 87.98B	44.65	10.93%	0.77%	24.21%	19.72%

* Healthcare Sector Average

Performance Comparison

DE:G51 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:G51	Genscript Biotech Corporation	3.76	1.97	109.70%
HK:2269	Wuxi Biologics (Cayman)	48.88	14.40	41.76%
HK:3759	Pharmaron Beijing Co., Ltd. Class H	29.68	5.81	24.34%
HK:1521	Frontage Holdings Corp.	2.10	1.01	92.20%
HK:1873	Viva Biotech Holdings	1.30	-0.88	-40.14%
HK:6821	Asymchem Laboratories (Tianjin) Co., Ltd. Class H	123.70	40.50	48.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Genscript Biotech AI Stock Analysis